Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic

Clinical Infectious Diseases

Volumn 61, Issue 8, 2015, Pages 1315-1321

  Burdette, Steven D ^a   Trotman, Robin ^b  

^a WRIGHT STATE UNIVERSITY   (United States)

^b CoxHealth Infectious Diseases ^*  (United States)

Author keywords

ABSSSI; Linezolid; MRSA; Oxazolidinone; Tedizolid

Indexed keywords

LINEZOLID; TEDIZOLID; ANTIINFECTIVE AGENT; ORGANOPHOSPHATE; OXAZOLE DERIVATIVE;

ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTEREMIA; BACTERIAL SKIN DISEASE; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DYSPEPSIA; HEADACHE; HUMAN; INSOMNIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; OBESITY; OPTIC NERVE DISEASE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; VOMITING; ANTIBIOTIC RESISTANCE; CHEMISTRY; DRUG EFFECTS; DRUG INTERACTION; GRAM-POSITIVE BACTERIAL INFECTIONS; MICROBIOLOGY; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL SKIN INFECTIONS;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LINEZOLID; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; ORGANOPHOSPHATES; OXAZOLES; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL SKIN INFECTIONS;

EID: 84943328189     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ501     Document Type: Article

References (37)

1. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40:135-6.
2. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 1-38.
3. Stevens D, Bisno A, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:147-59.
4. Rybak JM, Marx K, Martin CA. Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance. Pharmacotherapy 2014; 34:1198-208.
5. Locke JB, Finn J, Hilgers M, et al. Structure-activity relationships of diverse oxazolidinones for linezolid resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Antimicrob Agents Chemother 2010; 54:5337-43.
6. Louie A, Liu W, Kulawy R, Drusano GL. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin susceptible and methicillin resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob Agents Chemother 2011; 55:3353-460.
7. Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action and mechanisms of resistance. Int J Antimicrob Agents 2004; 23: 1113-9.
8. Shaw KJ, Barbachyn MR. The oxazolidinones: past, present and future. Ann N Y Acad Sci 2011; 1241:48-70.
9. McCusker KP, Fujimori DG. The chemistry of peptidyltransferase center-targeted antibiotics: enzymatic resistance and approaches to countering resistance. ACS Chem Biol 2012; 7:64-72.
10. Cubist Pharmaceuticals. Sivextro [package insert]. Lexington, MA: Cubist Pharmaceuticals, 2014.
11. Prokocimer P, Bien P, Surber J, et al. Phase 2, randomized, doubleblind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2011; 55:583-92.
12. Flanagan SD, Bien PA, Muñoz KA, Minassian SL, Prokocimer PG. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug. Pharmacotherapy 2014; 34:240-50.
13. Kisgen JJ, Mansour H, Unger NR, Childs LM. Tedizolid: a new oxazolidinone antimicrobial. Am J Health Syst Pharm 2014; 71: 621-33.
14. Ong V, Flanagan S, Fang E, et al. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab Dispos 2014; 42:1275-84.
15. Flanagan S, Bartizal K, Minassian SL, Fang E, Prokocimer P. In vitro, in vivo, and clinical studies of tedizolid to assess the for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother 2013; 57:3060-6.
16. Lodise TP, Drusano GL. Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate. Clin Infect Dis 2014; 58(suppl 1):S28-34.
17. Housman ST, Pope JS, Russomanno J, et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother 2012; 56:2627-34.
18. Lemaire S, Van Bambeke F, Appelbaum PC, Tulkens PM. Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. J Antimicrob Chemother 2009; 64:1035-43.
19. Lepak AJ, Marchillo K, Pichereau S, CraigWA, Andes DR. Comparative pharmacodynamics of a new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model. Antimicrob Agents Chemother 2012; 56:5916-22.
20. Tessier PR, Keel RA, Hagihara M, Crandon JL, Nicolau DP. Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model. Antimicrob Agents Chemother 2012; 56:2342-6.
21. Schaadt R, Sweeney D, Shinabarger D, Zurenko G. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob Agents Chemother 2009; 53:3236-9.
22. Prokocimer P, Bien P, DeAnda C, Pillar CM, Bartizal K. In vitro activity and microbiological efficacy of tedizolid (TR-700) against gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2012; 56:4608-13.
23. O'Riordan W, Green S, Mehra P, De Anda C, Fang E, Prokocimer P. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary. Clin Infect Dis 2014; 58(suppl 1):S43-50.
24. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 2013; 309: 559-69.
25. Brown SD, Traczewski MM. Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges. Antimicrob Agents Chemother 2010; 54:2063-9.
26. Locke JB, Zurenko GE, Shaw KJ, Bartizal K. Tedizolid for the management of human infections: in vitro characteristics. Clin Infect Dis 2014; 58(suppl 1):S35-42.
27. Choi S, Im W, Bartizal K. Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillinsensitive Streptococcus pneumoniae. Antimicrob Agents Chemother 2012; 56:4713-7.
28. Sahm DF, Deane J, Bien PA, et al. Results of the Surveillance of Tedizolid Activity and Resistance Program: in vitro susceptibility of grampositive pathogens collected in 2011 and 2012 from the United States and Europe. Diagn Microbiol Infect Dis 2015; 81:112-8.
29. Chen H, Yang Q. In vitro antimicrobial activity of the novel oxazolidinone tedizolid and comparator agents against Staphylococcus aureus and linezolid-resistant gram-positive pathogens: a multicentre study in China. Int J Antimicrob Agents 2014; 44:276-7.
30. Livermore DM, Mushtaq S,Warner M,Woodford N. Activity of oxazolidinone TR-700 against linezolid-susceptible and-resistant staphylococci and enterococci. J Antimicrob Chemother 2009; 63:713-5.
31. Long KS, Vester B. Resistance to linezolid caused by modifications at its binding site on the ribosome. Antimicrob Agents Chemother 2012; 56: 603-12.
32. Moellering RC. Tedizolid: a novel oxazolidinone for gram-positive infections. Clin Infect Dis 2014; 58(suppl 1):S1-3.
33. Shaw KJ, Poppe S, Schaat R, et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother 2008; 52:4442-7.
34. Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin structure infections (ESTABLISH-2): a randomized, doubleblind, phase 3, non-inferiority trial. Lancet Infect Dis 2014; 14:696-705.
35. Shorr AF, Lodise TP, Corey GR, et al. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2015; 59:864-71.
36. Lodise TP, Fang E, Minassian SL, Prokocimer PG. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the phase 3 ESTABLISH trials. Antimicrob Agents Chemother 2014; 58:7198-204.
37. Prokocimer P, Bien P, Munoz KA, Aster R. Hematological effects of TR-701, linezolid, and placebo administered for 21 days in healthy subjects [poster F1-2069a]. In: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, 25-28 October 2008.